

**Wholesale Acquisition Cost Information for Colorado Prescribers VYVGART Hytrulo®
(efgartigimod alfa and hyaluronidase -qvfc)**

Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below.

NDC	argenx Product	Dosage Form	Strength	Unit Size	Price per mg	Wholesale Acquisition Cost*
73475-3102-3	VYVGART Hytrulo (efgartigimod alfa and hyaluronidase -qvfc)	Solution in Vial Injection	1,008 mg efgartigimod alfa and 11,200 Units hyaluronidase per 5.6 mL (180 mg/2,000 Units per mL) Single Dose Vial	Single Dose Vial	\$15.96/mg	\$16,088.46 as of December 2, 2024 1 vial per dose
73475-1221-1	VYVGART Hytrulo (efgartigimod alfa and hyaluronidase -qvfc)	Solution in Prefilled Syringe	Injection: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase per 5 mL (200 mg/2,000 units per mL) in a single-dose prefilled syringe	Single Dose Prefilled Syringe	\$16.73/mg	\$16,732 as of April 10, 2025 1 prefill syringe per dose

The price to acquire the product listed may differ from the WAC price listed. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company. Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” There are currently no generic prescription drugs in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed argenx product.

*Pricing as of April 10th 2025. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include other discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the products, and no comparisons should be made.

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

©2025 argenx. All rights reserved.

US-ESC-23-00218v3 4/2025